Cargando…

Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients

BACKGROUND: Numerous studies have shown autophagy affects cellular immune responses. This study aims to explore prognosis and immunotherapeutic biomarkers related to autophagy in colon adenocarcinoma (COAD). METHODS: Based on R software, we performed the ssGSEA, differential expression analysis, Kap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Taohua, Cai, Yunlong, Zhu, Jing, Liu, Yucun, Chen, Shanwen, Wang, Pengyuan, Rong, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900120/
https://www.ncbi.nlm.nih.gov/pubmed/36756126
http://dx.doi.org/10.3389/fimmu.2023.1064704
_version_ 1784882777471057920
author Yue, Taohua
Cai, Yunlong
Zhu, Jing
Liu, Yucun
Chen, Shanwen
Wang, Pengyuan
Rong, Long
author_facet Yue, Taohua
Cai, Yunlong
Zhu, Jing
Liu, Yucun
Chen, Shanwen
Wang, Pengyuan
Rong, Long
author_sort Yue, Taohua
collection PubMed
description BACKGROUND: Numerous studies have shown autophagy affects cellular immune responses. This study aims to explore prognosis and immunotherapeutic biomarkers related to autophagy in colon adenocarcinoma (COAD). METHODS: Based on R software, we performed the ssGSEA, differential expression analysis, Kaplan-Meier survival analysis, correlation analysis, and enrichment analysis. For wet experiment, we did qRT-PCR, immunohistochemistry and CCK-8 experiments. RESULTS: Using autophagy-related genes (ARGs) and the ssGSEA, COAD patients were divided into low and high autophagy groups. For immune score, stromal score, tumor purity, tumor infiltrating immune cells, co-signaling molecules, tumor mutational burden, microsatellite instability, mismatch repair, immune-related pathways, immune signatures, somatic mutations and subtype analysis, high autophagy group might benefit more from immunotherapy. Among 232 ARGs, IFNG was generally significantly correlated with tumor immunotherapy biomarkers (PD-L1, CD8A and cytotoxic T lymphocytes (CTL)). The disease-free survival of high IFNG group was significantly longer than that of low group. On above-mentioned immune-related research, the high IFNG group reached the same conclusion. The qRT-PCR and IHC analysis confirmed that IFNG was significantly higher expressed in dMMR samples compared to pMMR samples. For chemotherapy, the autophagy and IFNG were significantly negatively related to the chemosensitivity to cisplatin; IFNG inhibitor glucosamine increased cisplatin chemoresistance while IFNG increased cisplatin chemosensitivity; IFNG could reverse glucosamine induced chemoresistance. The functional enrichment analysis of IFNG, PD-L1, CD8A and 20 similar proteins were related to the activation of the immune system. The GSEA and ceRNA network partly described interaction mechanisms of IFNG with PD-L1 and CD8A. CONCLUSION: Autophagy score and IFNG expression were novel immunotherapy predictive biomarkers, which might play predictive effects through the JAK-STAT signaling pathway. IFNG might be a potential targeted therapy for cisplatin resistant colon cancer. Besides, IFNG was also a prognostic indicator.
format Online
Article
Text
id pubmed-9900120
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99001202023-02-07 Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients Yue, Taohua Cai, Yunlong Zhu, Jing Liu, Yucun Chen, Shanwen Wang, Pengyuan Rong, Long Front Immunol Immunology BACKGROUND: Numerous studies have shown autophagy affects cellular immune responses. This study aims to explore prognosis and immunotherapeutic biomarkers related to autophagy in colon adenocarcinoma (COAD). METHODS: Based on R software, we performed the ssGSEA, differential expression analysis, Kaplan-Meier survival analysis, correlation analysis, and enrichment analysis. For wet experiment, we did qRT-PCR, immunohistochemistry and CCK-8 experiments. RESULTS: Using autophagy-related genes (ARGs) and the ssGSEA, COAD patients were divided into low and high autophagy groups. For immune score, stromal score, tumor purity, tumor infiltrating immune cells, co-signaling molecules, tumor mutational burden, microsatellite instability, mismatch repair, immune-related pathways, immune signatures, somatic mutations and subtype analysis, high autophagy group might benefit more from immunotherapy. Among 232 ARGs, IFNG was generally significantly correlated with tumor immunotherapy biomarkers (PD-L1, CD8A and cytotoxic T lymphocytes (CTL)). The disease-free survival of high IFNG group was significantly longer than that of low group. On above-mentioned immune-related research, the high IFNG group reached the same conclusion. The qRT-PCR and IHC analysis confirmed that IFNG was significantly higher expressed in dMMR samples compared to pMMR samples. For chemotherapy, the autophagy and IFNG were significantly negatively related to the chemosensitivity to cisplatin; IFNG inhibitor glucosamine increased cisplatin chemoresistance while IFNG increased cisplatin chemosensitivity; IFNG could reverse glucosamine induced chemoresistance. The functional enrichment analysis of IFNG, PD-L1, CD8A and 20 similar proteins were related to the activation of the immune system. The GSEA and ceRNA network partly described interaction mechanisms of IFNG with PD-L1 and CD8A. CONCLUSION: Autophagy score and IFNG expression were novel immunotherapy predictive biomarkers, which might play predictive effects through the JAK-STAT signaling pathway. IFNG might be a potential targeted therapy for cisplatin resistant colon cancer. Besides, IFNG was also a prognostic indicator. Frontiers Media S.A. 2023-01-23 /pmc/articles/PMC9900120/ /pubmed/36756126 http://dx.doi.org/10.3389/fimmu.2023.1064704 Text en Copyright © 2023 Yue, Cai, Zhu, Liu, Chen, Wang and Rong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yue, Taohua
Cai, Yunlong
Zhu, Jing
Liu, Yucun
Chen, Shanwen
Wang, Pengyuan
Rong, Long
Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title_full Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title_fullStr Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title_full_unstemmed Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title_short Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients
title_sort autophagy-related ifng is a prognostic and immunochemotherapeutic biomarker of coad patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900120/
https://www.ncbi.nlm.nih.gov/pubmed/36756126
http://dx.doi.org/10.3389/fimmu.2023.1064704
work_keys_str_mv AT yuetaohua autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT caiyunlong autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT zhujing autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT liuyucun autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT chenshanwen autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT wangpengyuan autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients
AT ronglong autophagyrelatedifngisaprognosticandimmunochemotherapeuticbiomarkerofcoadpatients